Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Non-Current Deferred Tax Liability of $166.0 million for Q1 2026, up 0.61% year-over-year from $165.0 million in Q1 2025, and up 0.61% quarter-over-quarter from $165.0 million in Q1 2025.
Dr Reddys Laboratories (RDY) Non-Current Deferred Tax Liability (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Non-Current Deferred Tax Liability history runs 10 years deep, the most recent figure standing at $166.0 million for Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability rose 0.61% year-over-year to $166.0 million; the TTM figure through Mar 2026 stood at $166.0 million (up 0.61% YoY), while the FY2026 annual figure was $166.0 million, up 0.61% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $166.0 million, up from $165.0 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $166.0 million in Q1 2026, with the low at $1.0 million in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $11.0 million (2024), against an average of $70.6 million.
- The sharpest annual moves came in 2022 and 2025: Non-Current Deferred Tax Liability sank 80.0% in 2022, then jumped 1400.0% in 2025.
- Dr Reddys Laboratories' Non-Current Deferred Tax Liability stood at $1.0 million in 2022, then surged by 900.0% to $10.0 million in 2023, then climbed by 10.0% to $11.0 million in 2024, then surged by 1400.0% to $165.0 million in 2025, then advanced by 0.61% to $166.0 million in 2026.
- Business Quant data shows RDY's Non-Current Deferred Tax Liability at $166.0 million in Q1 2026, $165.0 million in Q1 2025, and $11.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166.00 Mn |
| Mar 31, 2026 | 166.00 Mn |
| Mar 31, 2025 | 165.00 Mn |
| Mar 31, 2025 | 165.00 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Mar 31, 2024 | 11.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Mar 31, 2022 | 1.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2020 | 4.00 Mn |
| Mar 31, 2020 | 4.00 Mn |
| Mar 31, 2019 | 9.00 Mn |
| Mar 31, 2019 | 9.00 Mn |
| Mar 31, 2018 | 11.00 Mn |
| Mar 31, 2018 | 11.00 Mn |
| Dec 31, 2009 | 60.00 Mn |
| Dec 31, 2009 | 60.00 Mn |